Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded by StockNews.com to "Hold"

StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday. Separately, JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating on the stock in a report on […]

Related Keywords

Canada , ,Enanta Pharmaceuticals Inc ,Nisa Investment Advisors ,Institutional Investors Weigh In On Enanta Pharmaceuticals ,News Ratings For Enanta Pharmaceuticals Daily ,Tower Research Capital ,Enanta Pharmaceuticals ,Clearstead Advisors ,Royal Bank ,Analyst Recommendations For Enanta Pharmaceuticals ,Enanta Pharmaceuticals Company Profile ,Jpmorgan Chase Co ,Us Bancorp ,Enanta Pharmaceuticals Stock Performance ,Free Report ,Get Free Report ,Investment Advisors ,Research Capital ,Enanta Pharmaceuticals Daily ,